This bill, the Prescription Pricing for the People Act of 2025, directs the Federal Trade Commission (FTC) to study intermediaries in the prescription drug supply chain and report to Congress. The FTC must look at pharmacy benefit managers (PBMs) and other intermediaries and examine specific practices, including whether PBMs charge payers more than the reimbursement they give pharmacies, steer patients to pharmacies they own, audit or use proprietary pharmacy data for competitive advantage, and use formulary designs that affect drug market shares. The FTC must also examine competition trends, how companies decide to contract with intermediaries, legal or regulatory obstacles to enforcement, and factors that contribute to prescription drug costs. The FTC must include findings from a November 2017 roundtable and say what actions it plans to take. The bill requires an interim report within 180 days and a final report within 1 year. A separate report must list complaints about alleged anticompetitive conduct by sole-source drug manufacturers, describe the FTC's ability to bring enforcement actions against them, and recommend ways to strengthen enforcement.
The bill requires the FTC to gather information and produce reports with observations and recommendations about PBMs, pharmacy services organizations, sole-source drug manufacturers, and other intermediaries. It does not itself change prices, create new enforcement powers, or make immediate changes to benefits. The reports must describe any planned FTC actions and suggest policy or legislative changes Congress could consider.
No publicly available information.
The bill calls for improving transparency and competition in the pharmaceutical supply chain, preventing anticompetitive behavior, and ensuring consumers benefit from any cost savings from mergers and efficiencies. It asks the FTC to study problems, report findings, and recommend actions to address those concerns.
No publicly available information.